Orthofix Medical (OFIX) Projected to Announce Earnings on Monday

Orthofix Medical (NASDAQ:OFIX) is projected to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $210.52 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Wednesday, August 5th. The medical device company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.02. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. The business had revenue of $210.93 million for the quarter, compared to analysts’ expectations of $209.28 million. On average, analysts expect Orthofix Medical to post ($1.29) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.

Orthofix Medical Trading Down 11.8%

NASDAQ:OFIX opened at $7.87 on Friday. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $9.29 and its two-hundred day moving average is $10.99. Orthofix Medical has a 52 week low of $7.81 and a 52 week high of $16.42. The company has a market cap of $320.55 million, a PE ratio of -5.11 and a beta of 0.66.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OFIX. Weiss Ratings lowered Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Canaccord Genuity Group decreased their price target on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $14.75.

About Orthofix Medical

Orthofix Medical Inc is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions.

Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.